Abdur Rafay Bilal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdur Rafay Bilal has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Raheel Ahmed
Newcastle Hospitals NHS Foundation Trust, United Kingdom; Translational and Clinical Research Institute, Newcastle University, United Kingdom
3 shared publications Hateem Gaba
Department of Medicine Ziauddin Medical College Karachi Pakistan
2 shared publicationsS. M. Washaqul Arfin
Ziauddin Medical University Karachi Pakistan
2 shared publications- Saad Ahmed Waqas
Department of Medicine Dow University of Health Sciences Karachi Pakistan
2 shared publications - Shaheer Qureshi
Department of Medicine Dow University of Health Sciences Karachi Pakistan
2 shared publications - Abdur Raheem Bilal
Department of Medicine, Ziauddin Medical College, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 13 March 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70178
Closed‐Loop Automated Insulin Delivery in Patients With Type 2 Diabetes: A Meta‐Analysis of Randomised Controlled Trials
Aims: To evaluate the efficacy and safety of closed‐loop automated insulin delivery (AID) systems with the conventional insulin delivery arm in adults with type 2 diabetes mellitus (T2DM). Methods: A systematic review and meta‐analysis of 10 randomised controlled trials ( n = 786; AID: 436, control: 350) was conducted per PRISMA guidelines. Data from studies were pooled using a random‐effects model to derive weighted mean differences (WMDs) and 95% confidence intervals (CIs). Results: AID significantly increased time in normoglycemia (WMD: +22.14%; 95% CI: 17.05, 27.23; 319 min/day; P < 0.00001) and reduced hyperglycemia (WMD: −21.04%; 95% CI: −6.23, −15.84; −303 min/day; P < 0.00001), mean glucose (WMD: −1.54 mmol/L; 95% CI: −2.37, −0.70; P = 0.0003), and HbA1c (WMD: −0.80%; 95% CI: −1.48, −0.12; P < 0.00001). Glucose SD improved significantly (WMD: –0.46; 95% CI: −0.74, −0.18; P = 0.002). No significant differences were found in hypoglycemia (WMD: −0.11%; 95% CI: −0.32, 0.09; −1.6 min/day; P = 0.28), total daily insulin (WMD: +4.80 IU; 95% CI: −1.87, 11.47; P = 0.16), or CV (WMD: −0.52%; 95% CI: −2.08, 1.04; P = 0.52). Total adverse events were higher with AID (RR: 1.61; 95% CI: 1.20, 2.17; P = 0.002), but serious adverse events (RR: 1.61; 95% CI: 0.83, 3.13; P = 0.16) and severe hypoglycemia (OR: 2.13; 95% CI: 0.22,20.83; P = 0.52) were not significantly different. Conclusions: Closed‐loop AID significantly improves glycemic control in T2DM without increasing serious adverse events.
- 13 March 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70178
Open AccessClosed‐Loop Automated Insulin Delivery in Patients With Type 2 Diabetes: A Meta‐Analysis of Randomised Controlled Trials
Aims: To evaluate the efficacy and safety of closed‐loop automated insulin delivery (AID) systems with the conventional insulin delivery arm in adults with type 2 diabetes mellitus (T2DM). Methods: A systematic review and meta‐analysis of 10 randomised controlled trials ( n = 786; AID: 436, control: 350) was conducted per PRISMA guidelines. Data from studies were pooled using a random‐effects model to derive weighted mean differences (WMDs) and 95% confidence intervals (CIs). Results: AID significantly increased time in normoglycemia (WMD: +22.14%; 95% CI: 17.05, 27.23; 319 min/day; P < 0.00001) and reduced hyperglycemia (WMD: −21.04%; 95% CI: −6.23, −15.84; −303 min/day; P < 0.00001), mean glucose (WMD: −1.54 mmol/L; 95% CI: −2.37, −0.70; P = 0.0003), and HbA1c (WMD: −0.80%; 95% CI: −1.48, −0.12; P < 0.00001). Glucose SD improved significantly (WMD: –0.46; 95% CI: −0.74, −0.18; P = 0.002). No significant differences were found in hypoglycemia (WMD: −0.11%; 95% CI: −0.32, 0.09; −1.6 min/day; P = 0.28), total daily insulin (WMD: +4.80 IU; 95% CI: −1.87, 11.47; P = 0.16), or CV (WMD: −0.52%; 95% CI: −2.08, 1.04; P = 0.52). Total adverse events were higher with AID (RR: 1.61; 95% CI: 1.20, 2.17; P = 0.002), but serious adverse events (RR: 1.61; 95% CI: 0.83, 3.13; P = 0.16) and severe hypoglycemia (OR: 2.13; 95% CI: 0.22,20.83; P = 0.52) were not significantly different. Conclusions: Closed‐loop AID significantly improves glycemic control in T2DM without increasing serious adverse events.
- Open Access
- 21 February 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70102
Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta‐Analysis
Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) have demonstrated promising effects in promoting weight loss and improving metabolic markers. However, their effectiveness post‐bariatric surgery remains uncertain. Methods: PubMed, Cochrane CENTRAL, and Scopus were queried through March 2025 for randomised controlled trials comparing GLP‐1RA to placebo in post‐bariatric surgery patients. Outcomes included weight loss, BMI, total cholesterol, triglycerides, fasting blood glucose, blood pressure, HbA1c, and adverse events. Random‐effects models were used to calculate standardised mean differences (SMDs), weighted mean differences (WMDs), and risk ratios (RRs). Results: Six trials ( n = 401) were included. GLP‐1RA significantly reduced weight (SMD: −5.96 kg [95% CI: −9.40, −2.53]; p = 0.0007), BMI (WMD: −3.08 kg/m 2 [95% CI: −4.16, −2.00]; p < 0.00001), total cholesterol (WMD: −0.30 mmol/L / −11.60 mg/dL [95% CI: −0.50, −0.09 / −19.34, −3.48]; p = 0.005), and HbA1c (WMD: −0.39% [95% CI: −0.62, −0.17]; p = 0.0007). Total adverse events (RR: 1.49 [95% CI: 1.14, 1.94]; p = 0.003) and nausea (RR: 2.23 [95% CI: 1.21, 4.09]; p = 0.010) were more common with GLP‐1RA compared to placebo. No significant changes were found in blood pressure, triglycerides, or fasting blood glucose. Conclusions: GLP‐1RAs significantly reduce weight, BMI, HbA1c, and total cholesterol in patients following bariatric surgery. These findings highlight the potential of GLP‐1RA therapy post‐bariatric surgery. Future research is warranted to assess the long‐term effects of GLP‐1RA on the post‐operative metabolic profile.
- 21 February 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70102
Open AccessEfficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta‐Analysis
Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) have demonstrated promising effects in promoting weight loss and improving metabolic markers. However, their effectiveness post‐bariatric surgery remains uncertain. Methods: PubMed, Cochrane CENTRAL, and Scopus were queried through March 2025 for randomised controlled trials comparing GLP‐1RA to placebo in post‐bariatric surgery patients. Outcomes included weight loss, BMI, total cholesterol, triglycerides, fasting blood glucose, blood pressure, HbA1c, and adverse events. Random‐effects models were used to calculate standardised mean differences (SMDs), weighted mean differences (WMDs), and risk ratios (RRs). Results: Six trials ( n = 401) were included. GLP‐1RA significantly reduced weight (SMD: −5.96 kg [95% CI: −9.40, −2.53]; p = 0.0007), BMI (WMD: −3.08 kg/m 2 [95% CI: −4.16, −2.00]; p < 0.00001), total cholesterol (WMD: −0.30 mmol/L / −11.60 mg/dL [95% CI: −0.50, −0.09 / −19.34, −3.48]; p = 0.005), and HbA1c (WMD: −0.39% [95% CI: −0.62, −0.17]; p = 0.0007). Total adverse events (RR: 1.49 [95% CI: 1.14, 1.94]; p = 0.003) and nausea (RR: 2.23 [95% CI: 1.21, 4.09]; p = 0.010) were more common with GLP‐1RA compared to placebo. No significant changes were found in blood pressure, triglycerides, or fasting blood glucose. Conclusions: GLP‐1RAs significantly reduce weight, BMI, HbA1c, and total cholesterol in patients following bariatric surgery. These findings highlight the potential of GLP‐1RA therapy post‐bariatric surgery. Future research is warranted to assess the long‐term effects of GLP‐1RA on the post‐operative metabolic profile.
- Open Access
- 29 December 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (3) , 108538
Temporal trends in heart failure and stroke-related mortality in the United States, 1999–2023
- 29 December 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (3) , 108538
Open AccessTemporal trends in heart failure and stroke-related mortality in the United States, 1999–2023